By expenditures
| Name | Title | Type |
|---|---|---|
| Tonja Boykin | Chief Operating Officer | Auditee |
| Kevin Matthews | FCCA CFE President | Auditee |
| Renee Ordeneaux | Partner | Auditee |
| No contacts on file | ||
| ID | Year | Date Accepted | Auditor | Spend |
|---|---|---|---|---|
| 387265 | 2024 | 2026-02-13 | NOVOGRADAC AND COMPANY LLP | $5.55M |
| 371940 | 2023 | 2025-11-07 | ARMANINO LLP | $30.26M |
| 325003 | 2022 | 2024-10-16 | Armanino | $8.82M |
| 294537 | 2021 | 2024-03-11 | Armanino | $2.23M |
| Audit | Year | Accepted | Finding | Ref | Severity | Repeat | Requirement |
|---|---|---|---|---|---|---|---|
| 387265 | 2024 | 2026-02-13 | 1173502 | 2024-002 | Material Weakness | Yes | I |
| 387265 | 2024 | 2026-02-13 | 1173501 | 2024-001 | Material Weakness | Yes | L |
| 387265 | 2024 | 2026-02-13 | 1173500 | 2024-002 | Material Weakness | Yes | I |
| 387265 | 2024 | 2026-02-13 | 1173499 | 2024-001 | Material Weakness | Yes | L |
| 387265 | 2024 | 2026-02-13 | 1173498 | 2024-002 | Material Weakness | Yes | I |
| 387265 | 2024 | 2026-02-13 | 1173497 | 2024-001 | Material Weakness | Yes | L |
| 387265 | 2024 | 2026-02-13 | 1173496 | 2024-002 | Material Weakness | Yes | I |
| 387265 | 2024 | 2026-02-13 | 1173495 | 2024-001 | Material Weakness | Yes | L |
| 371940 | 2023 | 2025-11-07 | 1162148 | 2023-008 | Material Weakness | Yes | I |
| 371940 | 2023 | 2025-11-07 | 1162147 | 2023-007 | Material Weakness | Yes | L |
| 371940 | 2023 | 2025-11-07 | 1162146 | 2023-008 | Material Weakness | Yes | I |
| 371940 | 2023 | 2025-11-07 | 1162145 | 2023-007 | Material Weakness | Yes | L |
| 371940 | 2023 | 2025-11-07 | 1162144 | 2023-008 | Material Weakness | Yes | I |
| 371940 | 2023 | 2025-11-07 | 1162143 | 2023-007 | Material Weakness | Yes | L |
| 371940 | 2023 | 2025-11-07 | 1162142 | 2023-008 | Material Weakness | Yes | I |
| 371940 | 2023 | 2025-11-07 | 1162141 | 2023-007 | Material Weakness | Yes | L |
| 325003 | 2022 | 2024-10-16 | 1079476 | 2022-007 | Significant Deficiency | - | I |
| 325003 | 2022 | 2024-10-16 | 1079475 | 2022-007 | Significant Deficiency | - | I |
| 325003 | 2022 | 2024-10-16 | 1079474 | 2022-007 | Significant Deficiency | - | I |
| 325003 | 2022 | 2024-10-16 | 1079473 | 2022-007 | Significant Deficiency | - | I |
| 325003 | 2022 | 2024-10-16 | 1079472 | 2022-007 | Significant Deficiency | - | I |
| 325003 | 2022 | 2024-10-16 | 1079471 | 2022-007 | Significant Deficiency | - | I |
| 325003 | 2022 | 2024-10-16 | 503034 | 2022-007 | Significant Deficiency | - | I |
| 325003 | 2022 | 2024-10-16 | 503033 | 2022-007 | Significant Deficiency | - | I |
| 325003 | 2022 | 2024-10-16 | 503032 | 2022-007 | Significant Deficiency | - | I |
| 325003 | 2022 | 2024-10-16 | 503031 | 2022-007 | Significant Deficiency | - | I |
| 325003 | 2022 | 2024-10-16 | 503030 | 2022-007 | Significant Deficiency | - | I |
| 325003 | 2022 | 2024-10-16 | 503029 | 2022-007 | Significant Deficiency | - | I |